Hyperion DeFi (HYPD) Stock Price, News & Analysis

Company Overview

Eyenovia, Inc. (NASDAQ: HYPD) is a clinical‐stage ophthalmic pharmaceutical company devoted to developing precision microdose therapies for eye disorders. The company’s proprietary Optejet microdosing platform is designed to deliver consistent, low-volume liquid medication directly to the ocular surface, aiming to enhance treatment efficacy while reducing systemic exposure and side effects common to traditional eyedrop applications.

The company’s lead pipeline candidates focus on myopia progression in pediatric patients and presbyopia in adults. Eyenovia’s ultra-low-dose atropine formulation is being investigated for myopia control, and its pilocarpine-based microdose therapy targets accommodation loss in presbyopia. In addition, the firm is advancing combination microdose products for intraocular pressure management in glaucoma, all utilizing the Optejet system to ensure accurate and reproducible dosing.

Founded in 2015 and headquartered in New York with research facilities in Massachusetts, Eyenovia has conducted multiple clinical trials across North America, Europe, and Asia. The company partners with leading academic institutions and contract research organizations to support its regulatory strategy and to progress its candidates through pivotal study phases, with the goal of securing approvals in key global markets.

At the helm of Eyenovia is Chairman and Chief Executive Officer Robert Blum, whose background in ophthalmic drug development forms the cornerstone of the company’s scientific and commercial vision. The senior leadership team brings together expertise in clinical operations, regulatory affairs, and vision care innovation, positioning Eyenovia to potentially transform the standard of care in ophthalmology.

Key Stats

• Today's Range: $11.80 to $14.30
• 50-Day Range: $1.04 to $15.96
• 52-Week Range: $0.85 to $124.80
• Volume: 911,979 shs
• Average Volume: 6.46 million shs
• Market Capitalization: $38.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Hold

Eyenovia Stock Analysis - MarketRank™

Eyenovia scored higher than 13% of companies evaluated by MarketBeat, and ranked 886th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Eyenovia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Eyenovia has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Eyenovia are expected to grow in the coming year, from ($41.60) to ($16.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eyenovia is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eyenovia is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.05% of the float of Eyenovia has been sold short.

Short Interest Ratio / Days to Cover

Eyenovia has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eyenovia has recently decreased by 31.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eyenovia does not currently pay a dividend.

Dividend Growth

Eyenovia does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.05% of the float of Eyenovia has been sold short.

Short Interest Ratio / Days to Cover

Eyenovia has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eyenovia has recently decreased by 31.49%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Eyenovia this week, compared to 2 articles on an average week.

Search Interest

14 people have searched for HYPD on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Eyenovia to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eyenovia insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.10% of the stock of Eyenovia is held by insiders.

Percentage Held by Institutions

Only 25.84% of the stock of Eyenovia is held by institutions.

HYPD Stock Analysis - Frequently Asked Questions

How have HYPD shares performed this year?

Eyenovia's stock was trading at $11.68 at the beginning of the year. Since then, HYPD stock has increased by 13.3% and is now trading at $13.23.

How were Eyenovia's earnings last quarter?

Eyenovia, Inc. (NASDAQ:HYPD) announced its quarterly earnings data on Monday, May, 19th. The company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($7.20) by $5.61. The business earned $1.60 million during the quarter, compared to analysts' expectations of $1.60 million.

When did Eyenovia's stock split?

Eyenovia shares reverse split on Monday, February 3rd 2025.The 1-80 reverse split was announced on Tuesday, January 28th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 31st 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Eyenovia?

Shares of HYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/19/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HYPD
• Previous Symbol: NASDAQ:EYEN
• CIK: 1682639
• Web: www.eyenovia.com
• Phone: (917) 289-1117
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Eyenovia: $2.00
• High Price Target: $2.00
• Low Price Target: $2.00
• Potential Upside/Downside: -84.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($58.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.82 million
• Net Margins: -62,238.41%
• Pretax Margin: -62,238.41%
• Return on Equity: N/A
• Return on Assets: -316.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.34
• Quick Ratio: 0.34

Sales & Book Value

• Annual Sales: $60 thousand
• Price / Sales: 632.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($695.52) per share
• Price / Book: -0.02

Miscellaneous

• Outstanding Shares: 2,880,000
• Free Float: 2,678,000
• Market Cap: $37.96 million
• Optionable: Optionable
• Beta: 2.47